{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,9,15]],"date-time":"2024-09-15T13:43:30Z","timestamp":1726407810591},"publisher-location":"Boston, MA","reference-count":92,"publisher":"Springer US","isbn-type":[{"type":"print","value":"9781461378372"},{"type":"electronic","value":"9781461561897"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[1998]]},"DOI":"10.1007\/978-1-4615-6189-7_8","type":"book-chapter","created":{"date-parts":[[2011,6,9]],"date-time":"2011-06-09T04:33:40Z","timestamp":1307594020000},"page":"135-157","source":"Crossref","is-referenced-by-count":0,"title":["Hormonal strategies for the prevention of breast cancer"],"prefix":"10.1007","author":[{"given":"Mark R.","family":"Olsen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard R.","family":"Love","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"8_CR1","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/S0140-6736(01)72307-0","volume":"2","author":"GT Beatson","year":"1896","unstructured":"Beatson GT. 1896. On the treatment of inoperable cases of carcinoma of the mamma: suggestions for a new method of treatment with illustrative cases. Lancet 2:104\u2013107.","journal-title":"Lancet"},{"key":"8_CR2","first-page":"45","volume-title":"Radiation Carcinogenesis: Epidemiology and Biological Significance","author":"M Tokunaga","year":"1984","unstructured":"Tokunaga M, Land CE, Yamamoto T, et al. 1984. Breast cancer among atomic bomb survivors. In Boice JD Jr, Fraumeni JF Jr, eds. Radiation Carcinogenesis: Epidemiology and Biological Significance. New York: Raven Press, pp. 45\u201355."},{"key":"8_CR3","doi-asserted-by":"publisher","first-page":"243","DOI":"10.2307\/3577254","volume":"112","author":"M Tokunaga","year":"1987","unstructured":"Tokunaga M, Land CE, Yamamoto T, et al. 1987. Incidence of female breast cancer among atomic bomb survivors, Hiroshima and Nagasaki, 1950\u20131980. Radiat Res 112:243\u2013272.","journal-title":"Radiat Res"},{"key":"8_CR4","first-page":"253","volume-title":"Health Effects of Exposure to Low Levels of Ionizing Radiation: BEIR V.","author":"Committee on the Biological Effects of Ionizing Radiations","year":"1990","unstructured":"Committee on the Biological Effects of Ionizing Radiations. 1990. Health Effects of Exposure to Low Levels of Ionizing Radiation: BEIR V. Washington, DC: National Academy Press, pp. 253\u2013267."},{"key":"8_CR5","first-page":"75","volume-title":"Smoking and Health","author":"T Hirayama","year":"1988","unstructured":"Hirayama T. 1988. Health effects of active and passive smoking. In Aoki M, Hisamian S, Taminoga S, eds. Smoking and Health 1987. Amsterdam: Elsevier, pp. 75\u201386."},{"key":"8_CR6","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1038\/bjc.1995.417","volume":"72","author":"D Ford","year":"1995","unstructured":"Ford D, Easton DF. 1995. The genetics of breast and ovarian cancer. Br J Cancer 72:805\u2013812.","journal-title":"Br J Cancer"},{"key":"8_CR7","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1126\/science.7545954","volume":"266","author":"Y Miki","year":"1993","unstructured":"Miki Y, Swensen J, Shattuck-Eidens D, et al. 1993. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 266:66\u201371.","journal-title":"Science"},{"key":"8_CR8","doi-asserted-by":"publisher","first-page":"2088","DOI":"10.1126\/science.8091231","volume":"265","author":"R Wooster","year":"1994","unstructured":"Wooster R, Neuhausen SL, Mangion J, et al. 1994. Localization of a breast cancer susceptibility gene, BRCA2, to chromosome 13q12\u201313. Science 265:2088\u20132090.","journal-title":"Science"},{"key":"8_CR9","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1038\/ng0396-303","volume":"12","author":"RA Jensen","year":"1996","unstructured":"Jensen RA, Thompson ME, Jetton TL, et al. 1996. BRCA1 is secreted and exhibits properties of a granin. Nat Genet 12:303\u2013308.","journal-title":"Nat Genet"},{"key":"8_CR10","doi-asserted-by":"publisher","first-page":"1831","DOI":"10.1056\/NEJM199112263252602","volume":"325","author":"M Swift","year":"1991","unstructured":"Swift M, Morrell D, Massey RB, et al. 1991. Incidence of cancer in 161 families affected by ataxia-telangiectasia. N Engl J Med 325:1831\u20131836.","journal-title":"N Engl J Med"},{"key":"8_CR11","first-page":"209","volume":"43","author":"B MacMahon","year":"1970","unstructured":"MacMahon B, Cole P, Lin TM, et al. 1970. Age at first birth and breast cancer risk. Bull WHO 43:209\u2013221.","journal-title":"Bull WHO"},{"key":"8_CR12","first-page":"1451","volume":"61","author":"J Russo","year":"1978","unstructured":"Russo J, Russo IH. 1978. DNA labeling index and structure of the rat mammary gland as determinants of its susceptibility to carcinogenesis. J Natl Cancer Inst 61:1451\u20131459.","journal-title":"J Natl Cancer Inst"},{"issue":"8","key":"8_CR13","first-page":"2677","volume":"40","author":"J Russo","year":"1980","unstructured":"Russo J, Russo IH. 1980. Influence of differentiation and cell kinetics on the susceptibility of the rat mammary gland to carcinogenesis. Cancer Res 40 (8, pt 1): 2677\u20132687.","journal-title":"Cancer Res"},{"key":"8_CR14","first-page":"497","volume":"100","author":"J Russo","year":"1980","unstructured":"Russo J, Russo IH. 1980. Susceptibility of the mammary gland to carcinogensis. II. Pregnancy interruption as a risk factor in tumor incidence. Am J Pathol 100:497\u2013512.","journal-title":"Am J Pathol"},{"key":"8_CR15","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1038\/bjc.1965.19","volume":"19","author":"GM McCormick","year":"1965","unstructured":"McCormick GM, Moon RC. 1965. Effect of pregnancy and lactation on growth of mammary tumors induced by 7,12-dimethylbenz(a)anthracene (DMBA). Br J Cancer 19:160\u2013166.","journal-title":"Br J Cancer"},{"key":"8_CR16","first-page":"47","volume":"109","author":"DR Ciocca","year":"1982","unstructured":"Ciocca DR, Parente A, Russo J. 1982. Endocrinologic milieu and susceptibility of the rat mammary gland to carcinogenesis. Am J Pathol 109:47\u201356.","journal-title":"Am J Pathol"},{"key":"8_CR17","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/978-1-4899-5043-7_3","volume-title":"The Mammary Gland Development, Regulation and Function","author":"J Russo","year":"1987","unstructured":"Russo J, Russo IH. 1987. Development of the human mammary gland. In Neville MC, Daniel C, eds. The Mammary Gland Development, Regulation and Function. New York: Plenum, pp. 67\u201393."},{"key":"8_CR18","first-page":"991","volume":"25","author":"TL Dao","year":"1960","unstructured":"Dao TL, Bock FG, Greiner MJ. 1960. Mammary carcinogenesis by 3-methylcholanthrene II. Inhibitory effect of pregnancy and lactation on tumor induction. J Nat! Cancer Inst 25:991\u20131003.","journal-title":"J Nat! Cancer Inst"},{"key":"8_CR19","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.1073\/pnas.45.8.1294","volume":"45","author":"C Huggins","year":"1959","unstructured":"Huggins C, Grand LC, Brillantes F. 1959. Critical significance of breast structure in the induction of mammary cancer in the rat. Proc Natl Acad Sci USA 45:1294\u20131300.","journal-title":"Proc Natl Acad Sci USA"},{"key":"8_CR20","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1177\/019262338301100207","volume":"11","author":"J Russo","year":"1983","unstructured":"Russo J. 1983. Basis of cellular autonomy in susceptibility to carcinogenesis. Toxicol Pathol 11:149\u2013166.","journal-title":"Toxicol Pathol"},{"key":"8_CR21","doi-asserted-by":"publisher","first-page":"3185","DOI":"10.1002\/1097-0142(19930515)71:10<3185::AID-CNCR2820711047>3.0.CO;2-C","volume":"71","author":"B MacMahon","year":"1993","unstructured":"MacMahon B. 1993. General Motors Cancer Research Prizewinners Laureates Lectures. Charles S. Mott Prize. Reproduction and cancer of the breast. Cancer 71:3185\u20133188.","journal-title":"Cancer"},{"key":"8_CR22","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1097\/00000478-198606000-00003","volume":"10","author":"TA Longacre","year":"1986","unstructured":"Longacre TA, Bartow SA. 1986. A correlative morphologic study of human breast and endometrium in the menstrual cycle. Am J Surg Pathol 10:382\u2013393.","journal-title":"Am J Surg Pathol"},{"key":"8_CR23","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1038\/bjc.1988.185","volume":"58","author":"CS Potten","year":"1988","unstructured":"Potten CS, Watson RJ, Williams GT, et al. 1988. The effect of age and menstrual cycle upon proliferative activity of the normal human breast. Br J Cancer 58:163\u2013170.","journal-title":"Br J Cancer"},{"issue":"5","key":"8_CR24","first-page":"495","volume":"13","author":"DV Spicer","year":"1995","unstructured":"Spicer DV, Krecker EA, Pike MC. 1995. The endocrine prevention of breast cancer. Cancer Invest 13(5):495\u2013504.","journal-title":"CancerInvest"},{"key":"8_CR25","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1038\/bjc.1982.213","volume":"46","author":"TJ Anderson","year":"1982","unstructured":"Anderson TJ, Ferguson DJP, Raab GM. 1982. Cell turnover in the `resting\u2019 human breast: influence of parity, contraceptive pill, age and laterality. Br J Cancer 46:376\u2013382.","journal-title":"Br J Cancer"},{"key":"8_CR26","first-page":"569","volume":"42","author":"EK Dawson","year":"1935","unstructured":"Dawson EK. 1935. A histological study of the normal mamma in relation to tumour growth: II The mature gland in pregnancy and lactation. Edin Med J 42:569\u2013598.","journal-title":"Edin Med J"},{"key":"8_CR27","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1210\/jcem-63-5-1174","volume":"63","author":"A Gompel","year":"1986","unstructured":"Gompel A, Malet C, Spritzer P, et al. 1986. Progestin effect on cell proliferation and 17 beta-hydroxysteroid dehydrogenase activity in normal human breast cells in culture. J Clin Endocrinol Metab 63:1174\u20131180.","journal-title":"J Clin Endocrinol Metab"},{"key":"8_CR28","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1210\/jcem-56-6-1124","volume":"56","author":"F Vignon","year":"1983","unstructured":"Vignon F, Bardon S, Chalbos D, Rochefort H. 1983. Antiestrogenic effect of R5020, a synthetic progestin, in human breast cancer cells in culture. J Clin Endocrinol Metab 56:1124\u20131130.","journal-title":"J Clin Endocrinol Metab"},{"key":"8_CR29","first-page":"599","volume":"49","author":"LC Murphy","year":"1989","unstructured":"Murphy LC, Dotzlaw H. 1989. Endogenous growth factor expression in T47D, human breast cancer cells, associated with reduced sensitivity to antiproliferative effects of progestins and antiestrogens. Cancer Res 49:599\u2013604.","journal-title":"Cancer Res"},{"key":"8_CR30","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1093\/oxfordjournals.aje.a113184","volume":"144","author":"LD Cowan","year":"1981","unstructured":"Cowan LD, Gordis L, Tonascia JA, et al. 1981. Breast cancer incidence in women with a history of progesterone deficiency. Am J Epidemiol 144:209\u2013217.","journal-title":"Am J Epidemiol"},{"key":"8_CR31","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1001\/jama.1983.03330280003002","volume":"249","author":"ER Gonzalez","year":"1983","unstructured":"Gonzalez ER. 1983. Chronic anovulation may increase postmenopausal breast cancer risk. JAMA 249:445\u2013446.","journal-title":"JAMA"},{"key":"8_CR32","doi-asserted-by":"publisher","first-page":"1414","DOI":"10.1016\/S0140-6736(83)90935-2","volume":"2","author":"MC Pike","year":"1983","unstructured":"Pike MC, Henderson BE, Krailo MD, et al. 1983. Breast cancer and oral contraceptives: reply to critics. Lancet 2:1414.","journal-title":"Lancet"},{"key":"8_CR33","first-page":"624","volume":"1","author":"Royal College of General Practitioners","year":"1977","unstructured":"Royal College of General Practitioners. 1977. Effect on hypertension and benign breast disease of progestagen component in combined oral contraceptives. Lancet 1:624\u2013626.","journal-title":"Lancet"},{"key":"8_CR34","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1038\/bjc.1989.237","volume":"60","author":"MC Pike","year":"1989","unstructured":"Pike MC, Ross RK, Lobo RA, et al. 1989. LHRH agonists and the prevention of breast and ovarian cancer. Br J Cancer 60:142\u2013148.","journal-title":"Br J Cancer"},{"key":"8_CR35","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/0277-5379(88)90173-3","volume":"24","author":"TJA Key","year":"1988","unstructured":"Key TJA, Pike MC. 1988. The role of oestrogens and progestagens in the epidemiology and prevention of breast cancer. Eur J Cancer Clin Oncol 24:29\u201343.","journal-title":"Eur J Cancer Clin Oncol"},{"key":"8_CR36","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1007\/978-94-011-3742-3_5","volume-title":"Approaches to Breast Cancer Prevention","author":"JO Drife","year":"1991","unstructured":"Drife JO. 1991. Avoiding hormone-related risk factors. In Stoll BA, ed. Approaches to Breast Cancer Prevention. Dordrecht: Kluwer, pp. 61\u201372."},{"key":"8_CR37","doi-asserted-by":"crossref","first-page":"270","DOI":"10.3181\/00379727-174-41736","volume":"174","author":"JD Radcliffe","year":"1975","unstructured":"Radcliffe JD, Moon RC. 1975. Effect of N-(4-hydroxyphenyl)retinamide on food intake, growth, and mammary gland development in rats (41736). Proc Soc Exp Biol Med 174:270\u2013275.","journal-title":"Proc Soc Exp Biol Med"},{"key":"8_CR38","first-page":"1339","volume":"39","author":"RC Moon","year":"1979","unstructured":"Moon RC, Thompson HJ, Becci PJ, et al. 1979. N-(4-hydroxyphenyl) retinamide, a new retinoid for prevention of breast cancer in the rat. Cancer Res 39:1339\u20131346.","journal-title":"Cancer Res"},{"key":"8_CR39","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1016\/0006-2952(91)90563-K","volume":"41","author":"R Bhatnagar","year":"1991","unstructured":"Bhatnagar R, Abou-Issa H, Curley RW Jr, et al. 1991. Growth suppression of human breast carcinoma cells in culture by N-(4-hydroxyphenyl)retinamide and its glucuronide and through synergism with glucarate. Biochem Pharmacol 41:1471\u20131477.","journal-title":"Biochem Pharmacol"},{"key":"8_CR40","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1016\/0277-5379(91)90309-2","volume":"27","author":"N Rotmensz","year":"1991","unstructured":"Rotmensz N, DePalo G, Formelli F, et al. 1991. Long-term tolerability of fenretinide (4-HPR) in breast cancer patients. Eur J Cancer 27:1127\u20131131.","journal-title":"Eur J Cancer"},{"key":"8_CR41","first-page":"6149","volume":"49","author":"F Formelli","year":"1989","unstructured":"Formelli F, Carsana R, Costa A, et al. 1989. Plasma retinol level reduction by the synthetic retinoid fenretinide: a one year follow-up study of breast cancer patients. Cancer Res 49:6149\u20136152.","journal-title":"Cancer Res"},{"key":"8_CR42","first-page":"93","volume":"12","author":"U Veronesi","year":"1992","unstructured":"Veronesi U, DePalo G, Costa A, et al. 1992. Chemoprevention of breast cancer with retinoids. Monogr Natl Cancer Inst 12:93\u201397.","journal-title":"Monogr Natl Cancer Inst"},{"key":"8_CR43","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/0964-1955(92)90035-Y","volume":"28B","author":"F Chiesa","year":"1992","unstructured":"Chiesa F, Tradati N, Marazza M, et al. 1992. Prevention of local relapses and new localisations of oral leukoplakias with the synthetic retinoid fenretinide (4-HPR). Preliminary results. Eur J Cancer B Oral Oncol 28B:97\u2013102.","journal-title":"Eur J Cancer B Oral Oncol"},{"issue":"275","key":"8_CR44","first-page":"A1643","volume":"33","author":"MK Gupta","year":"1992","unstructured":"Gupta MK, Posch A, Budd T, et al. (Cleveland Clinic). 1992. Inhibition of IGF-I- and IGEII-induced growth of human breast cancer cells (MCF-7) by N-(4-hydroxyphenyl) retinamide. Proc Annu Meet Am Assoc Cancer Res 33(275):A1643.","journal-title":"Proc Annu Meet Am Assoc Cancer Res"},{"key":"8_CR45","first-page":"4769","volume":"53","author":"R Torrisi","year":"1993","unstructured":"Torrisi R, Pansa F, Orengo M, et al. 1993. The synthetic retinoid fenretinide lowers plasma insulin-like growth factor I levels in breast cancer patients. Cancer Res 53:4769\u20134771.","journal-title":"Cancer Res"},{"issue":"90","key":"8_CR46","first-page":"A541","volume":"33","author":"H Abou-Issa","year":"1992","unstructured":"Abou-Issa H, Wilcox KA, Webb TE. 1992. Signal transduction system may mediate the growth-inhibitory effects of retinoids and calcium glucarate in the rat mammary tumor model. Proc Annu Meet Am Assoc Cancer Res 33(90):A541.","journal-title":"Proc Annu Meet Am Assoc Cancer Res"},{"key":"8_CR47","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1126\/science.8197458","volume":"264","author":"S Halachmi","year":"1994","unstructured":"Halachmi S, Marden E, Martin G, et al. 1994. Estrogen receptor-associated proteins: possible mediators of hormone-induced transcription. Science 264:1455\u20131458.","journal-title":"Science"},{"key":"8_CR48","first-page":"4472","volume":"49","author":"TA Ratko","year":"1989","unstructured":"Ratko TA, Detrisac CJ, Dinger NM, et al. 1989. Chemopreventive efficacy of combined retinoid and tamoxifen treatment following surgical excision of a primary mammary cancer in female rats. Cancer Res 49:4472\u20134476.","journal-title":"Cancer Res"},{"key":"8_CR49","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1200\/JCO.1993.11.3.474","volume":"11","author":"MA Cobleigh","year":"1993","unstructured":"Cobleigh MA, Dowlatshahi K, Deutsch TA, et al. 1993. Phase I\/II trial of tamoxifen with or without fenretinide, an analogue of vitamin A, in women with metastatic breast cancer. J Clin Oncol 11:474\u2013477.","journal-title":"J Clin Oncol"},{"key":"8_CR50","first-page":"51","volume":"21","author":"MA Cobleigh","year":"1993","unstructured":"Cobleigh MA, Lincoln S, Mullane M, Benson AB, Minn F. 1993. Phase I\/II trial of tamoxifen (tam) + fenretinide (4HPR) in Stage IV, receptor-positive, previously-untreated breast cancer. Breast Cancer Res Treat 21:51.","journal-title":"Breast Cancer Res Treat"},{"key":"8_CR51","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1677\/joe.0.0370083","volume":"37","author":"MJK Harper","year":"1967","unstructured":"Harper MJK, Walpole AL. 1967. Mode of action of ICI 46,474 in preventing implantation in rats. J Endocrinol 37:83\u201392.","journal-title":"J Endocrinol"},{"key":"8_CR52","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1111\/j.1471-0528.1973.tb11230.x","volume":"80","author":"JG Williamson","year":"1973","unstructured":"Williamson JG, Ellis JD. 1973. The induction of ovulation by tamoxifen. J Obstet Gynecol Br Common 80:844\u2013847.","journal-title":"J Obstet Gynecol Br Common"},{"key":"8_CR53","first-page":"3","volume-title":"Long-Term Tamoxifen Treatment for Breast Cancer","author":"VC Jordan","year":"1994","unstructured":"Jordan VC. 1994. The development of tamoxifen for breast cancer therapy. In Jordan VC, ed. Long-Term Tamoxifen Treatment for Breast Cancer. Madison: University of Wisconsin, pp. 3\u201326."},{"key":"8_CR54","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1038\/256592a0","volume":"256","author":"ME Lippman","year":"1975","unstructured":"Lippman ME, Bolan G. 1975. Oestrogen-responsive human breast cancer in long term tissue culture. Nature 256:592\u2013593.","journal-title":"Nature"},{"key":"8_CR55","first-page":"49","volume-title":"Use of the DMBA-induced rat mammary carcinoma system for the evaluation of tamoxifen as a potential adjuvant therapy","author":"VC Jordan","year":"1978","unstructured":"Jordan VC. 1978. Use of the DMBA-induced rat mammary carcinoma system for the evaluation of tamoxifen as a potential adjuvant therapy. Rev Endocr Rel Cancer (October supplement):49\u201355."},{"key":"8_CR56","first-page":"19","volume-title":"Adjuvant Therapy of Cancer","author":"VC Jordan","year":"1979","unstructured":"Jordan VC, Dix CJ, Allen KE. 1979. The effectiveness of long-term treatment in a laboratory model for adjuvant hormone therapy of breast cancer. In Salmon SE, Jones SE, eds. Adjuvant Therapy of Cancer, vol. 2. New York: Grune and Stratton, pp. 19\u201326."},{"key":"8_CR57","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1210\/edrv-11-4-578","volume":"11","author":"VC Jordan","year":"1990","unstructured":"Jordan VC, Murphy CS. 1990. Endocrine pharmacology of antiestrogens as antitumor agents. Endocr Rev 11:578\u2013610.","journal-title":"Endocr Rev"},{"key":"8_CR58","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1677\/joe.0.0830401","volume":"83","author":"P Daniel","year":"1979","unstructured":"Daniel P, Gaskell SJ, Bishhop H, Nicholson RI. 1979. Determination of tamoxifen and an hydroxylated metabolite in plasma from patients with advanced breast cancer using gas chromatography-mass spectrometry. J Endocrinol 83:401\u2013408.","journal-title":"J Endocrinol"},{"key":"8_CR59","first-page":"57","volume-title":"Long-Term Tamoxifen Treatment for Breast Cancer","author":"RR Love","year":"1994","unstructured":"Love RR. 1994. Multisystem biological and symptomatic toxicity of tamoxifen in postmenopausal women. In Jordan VC, ed. Long-Term Tamoxifen Treatment for Breast Cancer. Madison: University of Wisconsin, pp. 57\u201381."},{"key":"8_CR60","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1038\/bjc.1991.395","volume":"64","author":"KJ Walker","year":"1991","unstructured":"Walker KJ, Price-Thomas JM, Candlish W, et al. 1991. Influence of the antioestrogen tamoxifen on normal breast tissue. Br J Cancer 64:764\u2013768.","journal-title":"Br J Cancer"},{"key":"8_CR61","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0140-6736(92)90997-H","volume":"339","author":"Early Breast Cancer Trialists\u2019 Collaborative Group","year":"1992","unstructured":"Early Breast Cancer Trialists\u2019 Collaborative Group. 1992. Systemic treatment of early breast cancer by hormonal, cytotoxic or immune therapy. 133 randomized trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Lancet 339:1\u201315, 71\u201385.","journal-title":"Lancet"},{"key":"8_CR62","first-page":"1","volume-title":"Adjuvant Therapy of Breast Cancer-Tamoxifen Update. Bethesda","author":"National Cancer Institute","year":"1995","unstructured":"National Cancer Institute. 1995. Adjuvant Therapy of Breast Cancer-Tamoxifen Update. Bethesda, MD: NCI, pp. 1\u20137."},{"key":"8_CR63","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.1016\/0959-8049(94)00327-2","volume":"30A","author":"SR Johnston","year":"1994","unstructured":"Johnston SR, MacLennan KA, Sacks NP, Salter J, Smith IE, Dowsett M. 1994. Modulation of Bel-2 and Ki-67 expression in oestrogen receptor-positive human breast cancer by tamoxifen. Eur J Cancer 30A:1663\u20131669.","journal-title":"Eur J Cancer"},{"key":"8_CR64","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1038\/bjc.1995.527","volume":"72","author":"RR Perry","year":"1995","unstructured":"Perry RR, Kang Y, Greaves BR. 1995. Relationship between tamoxifen-induced transforming growth factor beta 1 expression, cytostasis and apoptosis in human breast cancer cells. Br J Cancer 72:1441\u20131446.","journal-title":"Br J Cancer"},{"key":"8_CR65","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/BF00689672","volume":"31","author":"AA Colletta","year":"1994","unstructured":"Colletta AA, Benson JR, Baum M. 1994. Alternative mechanisms of action of anti-oestrogens. Breast Cancer Res Treat 31:5\u20139.","journal-title":"Breast Cancer Res Treat"},{"key":"8_CR66","first-page":"4512","volume":"55","author":"A Kopp","year":"1995","unstructured":"Kopp A, Jonat W, Schmahl M, et al. 1995. Transforming growth factor beta 2 (TGF-beta 2) levels in plasma of patients with metastatic breast cancer treated with tamoxifen. Cancer Res 55:4512\u20134515.","journal-title":"Cancer Res"},{"key":"8_CR67","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1002\/1097-0142(19930701)72:1<131::AID-CNCR2820720125>3.0.CO;2-Z","volume":"72","author":"S Noguchi","year":"1993","unstructured":"Noguchi S, Motomura K, Inaji H, Imaoka S, Koyama H. 1993. Down-regulation of transforming growth factor-alpha by tamoxifen in human breast cancer. Cancer 72:131\u2013136.","journal-title":"Cancer"},{"key":"8_CR68","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/1097-0142(19930701)72:1<1::AID-CNCR2820720102>3.0.CO;2-F","volume":"72","author":"VC Jordan","year":"1993","unstructured":"Jordan VC. 1993. Growth factor regulation by tamoxifen is demonstrated in patients with breast cancer. Cancer 72:1\u20132.","journal-title":"Cancer"},{"key":"8_CR69","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/S0140-6736(89)91141-0","volume":"1","author":"T Fornander","year":"1989","unstructured":"Fornander T, Rutqvist LE, Cedermark B, et al. 1989. Adjuvant tamoxifen in early breast cancer: occurrence of new primary cancers. Lancet 1:117\u2013120.","journal-title":"Lancet"},{"key":"8_CR70","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1056\/NEJM198902233200802","volume":"320","author":"B Fisher","year":"1989","unstructured":"Fisher B, Costantino J, Redmond C, et al. 1989. A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogenreceptor-positive tumors. N Engl J Med 320:479\u2013484.","journal-title":"N Engl J Med"},{"key":"8_CR71","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1038\/bjc.1989.235","volume":"60","author":"TJ Powles","year":"1989","unstructured":"Powles TJ, Hardy JR, Ashley SE, et al. 1989. A pilot trial to evaluate the acute toxicity and feasibility of tamoxifen for prevention of breast cancer. Br J Cancer 60:126\u2013131.","journal-title":"Br J Cancer"},{"key":"8_CR72","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1007\/BF00689678","volume":"31","author":"TJ Powles","year":"1994","unstructured":"Powles TJ, Jones AL, Ashley SE, et al. 1994. The Royal Marsden Hospital pilot tamoxifen chemoprevention trial. Breast Cancer Res Treat 31:73\u201382.","journal-title":"Breast Cancer Res Treat"},{"key":"8_CR73","doi-asserted-by":"publisher","first-page":"1879","DOI":"10.1093\/jnci\/81.24.1879","volume":"81","author":"MH Gail","year":"1989","unstructured":"Gail MH, Brinton LA, Byar DP, et al. 1989. Projecting individualized probabilites of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst 81:1879\u20131886.","journal-title":"J Natl Cancer Inst"},{"key":"8_CR74","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1093\/jnci\/86.8.620","volume":"86","author":"ML Bondy","year":"1994","unstructured":"Bondy ML, Lustbader ED, Halabi S, et al. 1994. Validation of a breast cancer risk assessment model in women with a positive family history. J Natl Cancer Inst 86:620\u2013625.","journal-title":"J Natl Cancer Inst"},{"key":"8_CR75","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1007\/978-94-011-3742-3_14","volume-title":"Approaches to Breast Cancer Prevention","author":"VG Vogel","year":"1991","unstructured":"Vogel VG, Love RR. 1991. High risk groups and cost strategies. In Stoll BA, ed. Approaches to Breast Cancer Prevention. Dordrecht: Kluwer, pp. 207\u2013220."},{"key":"8_CR76","doi-asserted-by":"publisher","first-page":"2585","DOI":"10.1001\/archinte.1994.00420220081009","volume":"154","author":"RR Love","year":"1994","unstructured":"Love RR, Barden HS, Mazess RB, et al. 1994. Effect of tamoxifen on lumbar spine bone mineral density in postmenopausal women after 5 years. Arch Intern Med 154:2585\u20132588.","journal-title":"Arch Intern Med"},{"key":"8_CR77","doi-asserted-by":"publisher","first-page":"1534","DOI":"10.1093\/jnci\/86.20.1534","volume":"86","author":"RR Love","year":"1994","unstructured":"Love RR, Wiebe DA, Feyzi JM, et al. 1994. Effects of tamoxifen on cardiovascular risk factors in postmenopausal women after 5 years of treatment. J Natl Cancer Inst 86:1534\u20131539.","journal-title":"J Natl Cancer Inst"},{"key":"8_CR78","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1200\/JCO.1996.14.1.78","volume":"14","author":"TJ Powles","year":"1996","unstructured":"Powles TJ, Hickish T, Kanis JA, et al. 1996. Effect of tamoxifen on bone mineral density measured by dual-energy x-ray absorptiometry in healthy premenopausal and postmenopausal women. J Clin Oncol 14:78\u201384.","journal-title":"J Clin Oncol"},{"key":"8_CR79","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1093\/jnci\/86.7.527","volume":"86","author":"B Fisher","year":"1994","unstructured":"Fisher B, Costantino JP, Redmond CK, et al. 1994. Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. J Natl Cancer Inst 86:527\u2013537.","journal-title":"J Natl Cancer Inst"},{"key":"8_CR80","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1093\/jnci\/87.9.645","volume":"87","author":"LE Rutqvist","year":"1995","unstructured":"Rutqvist LE, Johansson H, Signomklao T, et al. 1995. Adjuvant tamoxifen therapy for early stage breast cancer and second primary malignancies. Stockholm Breast Cancer Study Group. J Natl Cancer Inst 87:645\u2013651.","journal-title":"J Natl Cancer Inst"},{"key":"8_CR81","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1200\/JCO.1996.14.3.1018","volume":"14","author":"SG Nayfield","year":"1996","unstructured":"Nayfield SG, Gorin MB. 1996. Tamoxifen-associated eye disease - a review. J Clin Oncol 14: 1018\u20131026.","journal-title":"J Clin Oncol"},{"key":"8_CR82","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1200\/JCO.1995.13.2.513","volume":"13","author":"IA Jaiyesimi","year":"1995","unstructured":"Jaiyesimi IA, Buzdar AU, Decker DA, Hortobagyi GN. 1995. Use of tamoxifen for breast cancer: twenty-eight years later. J Clin Oncol 13:513\u2013529.","journal-title":"J Clin Oncol"},{"key":"8_CR83","doi-asserted-by":"publisher","first-page":"1488","DOI":"10.1093\/jnci\/83.20.1488","volume":"83","author":"VC Jordan","year":"1991","unstructured":"Jordan VC, Fritz NF, Langan-Fahey S, et al. 1991. Alteration of endocrine parameters in premenopausal women with breast cancer during long-term adjuvant therapy with tamoxifen as the single agent. J Natl Cancer Inst 83:1488\u20131491.","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"8_CR84","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1002\/bies.950150111","volume":"15","author":"TA Dickens","year":"1993","unstructured":"Dickens TA, Colletta AA. 1993. The pharmacological manipulation of members of the transforming growth factor beta family in the chemoprevention of breast cancer. Bioessays 15(1):71\u201374.","journal-title":"Bioessays"},{"key":"8_CR85","doi-asserted-by":"publisher","first-page":"28507","DOI":"10.1074\/jbc.270.48.28507","volume":"270","author":"C Hurd","year":"1995","unstructured":"Hurd C, Khattree N, Alban P, et al. 1995. Hormonal regulation of the p53 tumor suppressor protein in T47D human breast carcinoma cell line. J Biol Chem 270:28507\u201328510.","journal-title":"J Biol Chem"},{"issue":"3","key":"8_CR86","first-page":"529","volume":"10","author":"E Sapi","year":"1995","unstructured":"Sapi E, Flick MB, Gilmore-Hebert M, et al. 1995. Transcriptional regulation of the c-fms (CSF-1R) proto-oncogene in human breast carcinoma cells by glucocorticoids. Oncogene 10(3):529\u2013542.","journal-title":"Oncogene"},{"issue":"6","key":"8_CR87","doi-asserted-by":"publisher","first-page":"2622","DOI":"10.1210\/en.132.6.2622","volume":"132","author":"MH Jeng","year":"1993","unstructured":". Jeng MH, Langan-Fahey SM, Jordan VC. 1993. Estrogenic actions of RU486 in hormone-responsive MCF-7 human breast cancer cells. Endocrinology 132(6):2622\u20132630.","journal-title":"Endocrinology"},{"key":"8_CR88","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1093\/oxfordjournals.annonc.a058837","volume":"5","author":"F Boccardo","year":"1994","unstructured":"Boccardo F, Rubagotti A, Perrotta A, et al. 1994. Ovarian ablation versus goserelin with or without tamoxifen in pre-perimenopausal patients with advanced breast cancer: results of a multicentric Italian study. Ann Oncol 5:337\u2013342.","journal-title":"Ann Oncol"},{"key":"8_CR89","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/0010-7824(91)90019-C","volume":"44","author":"DV Spicer","year":"1991","unstructured":"Spicer DV, Shoupe D, Pike MC. 1991. GnRH agonists as contraceptive agents: predicted significantly reduced risk of breast cancer. Contraception 44:289\u2013310.","journal-title":"Contraception"},{"key":"8_CR90","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1016\/0010-7824(93)90095-O","volume":"47","author":"DV Spicer","year":"1993","unstructured":"Spicer DV, Pike MC, Pike A, et al. 1993. Pilot trial of a gonadotropin hormone agonist with replacement hormones as a prototype contraceptive to prevent breast cancer. Contraception 47:427\u2013444.","journal-title":"Contraception"},{"key":"8_CR91","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1093\/jnci\/86.6.431","volume":"86","author":"DV Spicer","year":"1994","unstructured":"Spicer DV, Ursin G, Parisky YR, et al. 1994. Changes in mammographic densities induced by a hormonal contraceptive designed to reduce breast cancer risk. J Natl Cancer Inst 86: 431\u2013436.","journal-title":"J Natl Cancer Inst"},{"key":"8_CR92","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1097\/00001622-199511000-00017","volume":"7","author":"A Traynor","year":"1995","unstructured":"Traynor A. 1995. Recent advances in hormonal therapy for cancer. Curr Opin Oncol 7: 572\u2013581.","journal-title":"Curr Opin Oncol"}],"container-title":["Cancer Treatment and Research","Biological and Hormonal Therapies of Cancer"],"original-title":[],"link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/978-1-4615-6189-7_8.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T11:40:22Z","timestamp":1619869222000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/978-1-4615-6189-7_8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1998]]},"ISBN":["9781461378372","9781461561897"],"references-count":92,"URL":"https:\/\/doi.org\/10.1007\/978-1-4615-6189-7_8","relation":{},"ISSN":["0927-3042"],"issn-type":[{"type":"print","value":"0927-3042"}],"subject":[],"published":{"date-parts":[[1998]]}}}